United Therapeutics (NASDAQ:UTHR) Given New $660.00 Price Target at TD Cowen

United Therapeutics (NASDAQ:UTHR) had its price target upped by research analysts at TD Cowen from $575.00 to $660.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s target price suggests a potential upside of 11.19% from the stock’s current price.

A number of other research firms have also recently issued reports on UTHR. HC Wainwright lifted their price target on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a research note on Monday, March 23rd. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $557.64.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $593.60 on Monday. The company’s fifty day moving average is $495.95 and its 200-day moving average is $473.67. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $607.89. The company has a market capitalization of $26.02 billion, a PE ratio of 21.24, a P/E/G ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.19 EPS. On average, analysts forecast that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $9,956,712.48. This represents a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total value of $4,654,145.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $63,688.30. This represents a 98.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 333,820 shares of company stock worth $165,495,478. 10.30% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC lifted its position in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Invesco Ltd. lifted its position in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.